Acquisition by Papp Timothy M. of 600000 shares of Durect subject to Rule 16b-3
| DRRX Stock | USD 0.52 0.02 4.00% |
Slightly above 54% of Durect's investors are presently thinking to get in. The analysis of overall sentiment of trading Durect stock suggests that some investors are interested at this time. Durect's investing sentiment can be driven by a variety of factors including economic data, Durect's earnings reports, geopolitical events, and overall market trends.
Filed transaction by Durect Officer Chief Financial Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Durect Fundamental Analysis
We analyze Durect's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Durect using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Durect based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Durect is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Durect Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Durect stock to make a market-neutral strategy. Peer analysis of Durect could also be used in its relative valuation, which is a method of valuing Durect by comparing valuation metrics with similar companies.
Peers
Durect Related Equities
| AQST | Aquestive Therapeutics | 7.06 | ||||
| ALKS | Alkermes Plc | 1.87 | ||||
| SNOA | Sonoma Pharmaceuticals | 1.26 | ||||
| NBIX | Neurocrine Biosciences | 0.32 | ||||
| AVDL | Avadel Pharmaceuticals | 0.11 | ||||
| TKNO | Alpha Teknova | 1.19 | ||||
| LFCR | Lifecore Biomedical | 1.43 | ||||
| COLL | Collegium Pharmaceutical | 1.93 | ||||
| RDHL | Redhill Biopharma | 2.17 | ||||
| ORGO | Organogenesis Holdings | 3.37 | ||||
| IRWD | Ironwood Pharmaceuticals | 4.84 | ||||
| SHPH | Shuttle Pharmaceuticals | 5.56 | ||||
| EVOK | Evoke Pharma | 7.85 |
Additional Tools for Durect Stock Analysis
When running Durect's price analysis, check to measure Durect's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Durect is operating at the current time. Most of Durect's value examination focuses on studying past and present price action to predict the probability of Durect's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Durect's price. Additionally, you may evaluate how the addition of Durect to your portfolios can decrease your overall portfolio volatility.